JP2009513669A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009513669A5 JP2009513669A5 JP2008538048A JP2008538048A JP2009513669A5 JP 2009513669 A5 JP2009513669 A5 JP 2009513669A5 JP 2008538048 A JP2008538048 A JP 2008538048A JP 2008538048 A JP2008538048 A JP 2008538048A JP 2009513669 A5 JP2009513669 A5 JP 2009513669A5
- Authority
- JP
- Japan
- Prior art keywords
- agent
- matrix
- drugs
- rate regulating
- hydrogel
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000011159 matrix material Substances 0.000 claims 27
- 230000001105 regulatory Effects 0.000 claims 8
- 239000003814 drug Substances 0.000 claims 7
- 239000000463 material Substances 0.000 claims 7
- 239000002775 capsule Substances 0.000 claims 5
- 239000003795 chemical substances by application Substances 0.000 claims 5
- 239000000032 diagnostic agent Substances 0.000 claims 5
- 229940079593 drugs Drugs 0.000 claims 5
- -1 polyoxyethylene Polymers 0.000 claims 3
- 239000002904 solvent Substances 0.000 claims 3
- CTPDSKVQLSDPLC-UHFFFAOYSA-N 2-(oxolan-2-ylmethoxy)ethanol Chemical compound OCCOCC1CCCO1 CTPDSKVQLSDPLC-UHFFFAOYSA-N 0.000 claims 2
- 229940039227 DIAGNOSTIC AGENTS Drugs 0.000 claims 2
- 229940074730 OPHTHAMOLOGIC DIAGNOSTIC AGENTS Drugs 0.000 claims 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims 2
- 239000003472 antidiabetic agent Substances 0.000 claims 2
- 239000003793 antidiarrheal agent Substances 0.000 claims 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 2
- 239000007903 gelatin capsule Substances 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- DNIAPMSPPWPWGF-UHFFFAOYSA-N propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims 2
- 230000001225 therapeutic Effects 0.000 claims 2
- BVDRUCCQKHGCRX-UHFFFAOYSA-N 2,3-dihydroxypropyl formate Chemical compound OCC(O)COC=O BVDRUCCQKHGCRX-UHFFFAOYSA-N 0.000 claims 1
- 229940030609 CALCIUM CHANNEL BLOCKERS Drugs 0.000 claims 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims 1
- 229940105329 Carboxymethylcellulose Drugs 0.000 claims 1
- 229940113118 Carrageenan Drugs 0.000 claims 1
- 210000003169 Central Nervous System Anatomy 0.000 claims 1
- 229940030606 DIURETICS Drugs 0.000 claims 1
- 108010010803 Gelatin Proteins 0.000 claims 1
- GHBFNMLVSPCDGN-UHFFFAOYSA-N Monoctanoin Chemical compound CCCCCCCC(=O)OCC(O)CO GHBFNMLVSPCDGN-UHFFFAOYSA-N 0.000 claims 1
- SNICXCGAKADSCV-JTQLQIEISA-N Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 claims 1
- 229960002715 Nicotine Drugs 0.000 claims 1
- 229920001007 Nylon 4 Polymers 0.000 claims 1
- 239000002202 Polyethylene glycol Substances 0.000 claims 1
- 229950008882 Polysorbate Drugs 0.000 claims 1
- 206010037211 Psychomotor hyperactivity Diseases 0.000 claims 1
- 239000000150 Sympathomimetic Substances 0.000 claims 1
- 206010049975 Uterine contractions during pregnancy Diseases 0.000 claims 1
- 230000002159 abnormal effect Effects 0.000 claims 1
- 150000001252 acrylic acid derivatives Chemical class 0.000 claims 1
- 239000000556 agonist Substances 0.000 claims 1
- 229940072056 alginate Drugs 0.000 claims 1
- 235000010443 alginic acid Nutrition 0.000 claims 1
- 229920000615 alginic acid Polymers 0.000 claims 1
- 239000002269 analeptic agent Substances 0.000 claims 1
- 239000000730 antalgic agent Substances 0.000 claims 1
- 239000004004 anti-anginal agent Substances 0.000 claims 1
- 230000001396 anti-anti-diuretic Effects 0.000 claims 1
- 230000001430 anti-depressive Effects 0.000 claims 1
- 230000001387 anti-histamine Effects 0.000 claims 1
- 239000002260 anti-inflammatory agent Substances 0.000 claims 1
- 229940121363 anti-inflammatory agents Drugs 0.000 claims 1
- 230000002421 anti-septic Effects 0.000 claims 1
- 239000003416 antiarrhythmic agent Substances 0.000 claims 1
- 239000000924 antiasthmatic agent Substances 0.000 claims 1
- 239000001961 anticonvulsive agent Substances 0.000 claims 1
- 239000000935 antidepressant agent Substances 0.000 claims 1
- 239000002111 antiemetic agent Substances 0.000 claims 1
- 239000000739 antihistaminic agent Substances 0.000 claims 1
- 239000002220 antihypertensive agent Substances 0.000 claims 1
- 239000003524 antilipemic agent Substances 0.000 claims 1
- 239000004599 antimicrobial Substances 0.000 claims 1
- 239000002282 antimigraine agent Substances 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 239000003096 antiparasitic agent Substances 0.000 claims 1
- 239000000939 antiparkinson agent Substances 0.000 claims 1
- 239000002221 antipyretic Substances 0.000 claims 1
- 239000003435 antirheumatic agent Substances 0.000 claims 1
- 229940121383 antituberculosis agents Drugs 0.000 claims 1
- 239000003699 antiulcer agent Substances 0.000 claims 1
- 239000003443 antiviral agent Substances 0.000 claims 1
- 239000002830 appetite depressant Substances 0.000 claims 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims 1
- 239000002876 beta blocker Substances 0.000 claims 1
- 230000002051 biphasic Effects 0.000 claims 1
- 239000000480 calcium channel blocker Substances 0.000 claims 1
- 239000001768 carboxy methyl cellulose Substances 0.000 claims 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims 1
- 239000002327 cardiovascular agent Substances 0.000 claims 1
- 239000000679 carrageenan Substances 0.000 claims 1
- 235000010418 carrageenan Nutrition 0.000 claims 1
- 229920001525 carrageenan Polymers 0.000 claims 1
- 229920003086 cellulose ether Polymers 0.000 claims 1
- 230000001276 controlling effect Effects 0.000 claims 1
- 235000014632 disordered eating Nutrition 0.000 claims 1
- 239000002934 diuretic Substances 0.000 claims 1
- 201000006180 eating disease Diseases 0.000 claims 1
- 238000005538 encapsulation Methods 0.000 claims 1
- 239000000945 filler Substances 0.000 claims 1
- 229920000159 gelatin Polymers 0.000 claims 1
- 239000008273 gelatin Substances 0.000 claims 1
- 235000019322 gelatine Nutrition 0.000 claims 1
- 235000011852 gelatine desserts Nutrition 0.000 claims 1
- 239000003193 general anesthetic agent Substances 0.000 claims 1
- 230000002068 genetic Effects 0.000 claims 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims 1
- 235000011187 glycerol Nutrition 0.000 claims 1
- 229920000591 gum Polymers 0.000 claims 1
- 230000000147 hypnotic Effects 0.000 claims 1
- 239000003326 hypnotic agent Substances 0.000 claims 1
- 230000036039 immunity Effects 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000003158 myorelaxant agent Substances 0.000 claims 1
- 239000003887 narcotic antagonist Substances 0.000 claims 1
- 229930015196 nicotine Natural products 0.000 claims 1
- 235000015097 nutrients Nutrition 0.000 claims 1
- 230000001734 parasympathetic Effects 0.000 claims 1
- 229920001223 polyethylene glycol Polymers 0.000 claims 1
- 229920000136 polysorbate Polymers 0.000 claims 1
- 230000003449 preventive Effects 0.000 claims 1
- 239000003368 psychostimulant agent Substances 0.000 claims 1
- 230000000580 secretagogue Effects 0.000 claims 1
- 230000001624 sedative Effects 0.000 claims 1
- 239000000932 sedative agent Substances 0.000 claims 1
- 239000007901 soft capsule Substances 0.000 claims 1
- 150000003431 steroids Chemical class 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 230000001975 sympathomimetic Effects 0.000 claims 1
- 230000002936 tranquilizing Effects 0.000 claims 1
- 239000003204 tranquilizing agent Substances 0.000 claims 1
- 239000000814 tuberculostatic agent Substances 0.000 claims 1
- 230000000261 vasodilator Effects 0.000 claims 1
- 239000003071 vasodilator agent Substances 0.000 claims 1
- 239000000230 xanthan gum Substances 0.000 claims 1
- 235000010493 xanthan gum Nutrition 0.000 claims 1
- 229920001285 xanthan gum Polymers 0.000 claims 1
- 229940082509 xanthan gum Drugs 0.000 claims 1
Claims (18)
- カプセルへの封入のための二重制御放出液体マトリクスであって、該マトリクスは:
(a) 親水性ベヒクルを含む、最初の速度調節バリア;
(b) 該親水性ベヒクル中に溶解または分散されたヒドロゲル形成ポリマー材料を含む第2の速度調節バリア;および
(c) 該最初の速度調節バリアおよび該第2の速度調節バリア中に溶解または分散された治療薬、予防薬、または診断薬
を含み、前記治療薬、予防薬、または診断薬の放出は二相性である、マトリクス。 - 請求項1に記載のマトリクスであって、前記第2の速度調節バリアが、前記最初の速度調節バリア中に溶解または分散される、マトリクス。
- 請求項1に記載のマトリクスであって、前記親水性ベヒクルが、ポリエチレングリコール、ポリオキシエチレン32ラウリルグリセリド、およびポリオキシエチレン8カプリル/カプリングリセリド、グリコフロールならびにポリソルベートからなる群より選択される、マトリクス。
- 請求項1に記載のマトリクスであって、前記親水性ベヒクルが、該マトリクスの約10重量%から約80重量%の量で存在する、マトリクス。
- 請求項3に記載のマトリクスであって、前記親水性ベヒクルが、該マトリクスの約20重量%から約60重量%の量で存在する、マトリクス。
- 請求項1に記載のマトリクスであって、前記親水性ベヒクルと混和できる一つまたはそれより多い溶媒をさらに含んでいる、マトリクス。
- 請求項6に記載のマトリクスであって、前記一つまたはそれより多い混和できる溶媒が、グリセリン、プロピレングリコール、エタノール、グリコフロールおよびCapmulMCM C8からなる群より選択される、マトリクス。
- 請求項6に記載のマトリクスであって、前記一つまたはそれより多い混和できる溶媒が、充填材料の約0重量%から約80重量%の量で存在する、マトリクス。
- 請求項1に記載のマトリクスであって、前記ヒドロゲル形成ポリマー材料が、セルロースエーテル、架橋されたアクリラート、アルギナート、ガーゴム、キサンタンガム、カラゲナン、カルボキシメチルセルロース、高分子量ポリピロリドン、およびそれらの混合物からなる群より選択される、マトリクス。
- 請求項1に記載のマトリクスであって、前記ヒドロゲル形成ポリマー材料が、該マトリクスの約3重量%から約80重量%の量で存在する、マトリクス。
- 請求項10に記載のマトリクスであって、前記ヒドロゲル形成ポリマー材料が、該マトリクスの約5重量%から約50重量%の量で存在する、マトリクス。
- 請求項1に記載のマトリクスであって、前記治療薬、予防薬、または診断薬が、興奮剤;鎮痛剤;麻酔剤;抗喘息剤;抗関節炎剤;抗癌剤;抗コリン作用剤;抗痙攣剤;抗うつ剤;抗糖尿病剤;下痢止め剤;抗嘔吐剤;抗寄生虫剤;抗ヒスタミン剤;抗高脂血症剤;抗高血圧剤;抗感染症剤;抗炎症剤;抗片頭痛剤;抗腫瘍剤;抗パーキンソン薬;止痒剤;抗不安薬;解熱剤;抗痙攣剤;抗結核薬;抗潰瘍剤;抗ウイルス剤;精神安定剤;食欲抑制剤(摂食障害剤);注意欠陥障害薬および注意力欠損高活動性異常薬;心血管剤(カルシウムチャンネルブロッカー、抗狭心症薬、中枢神経系(「CNS」)剤、ベータブロッカー、および抗不整脈剤を含む);中枢神経興奮薬;利尿剤;遺伝物質;ホルモン分解薬;催眠剤;血糖降下剤;免疫抑制剤;筋弛緩剤;麻薬拮抗薬;ニコチン;栄養剤;副交感神経遮断薬;ペプチド薬;精神刺激薬;鎮静剤;唾液分泌促進剤;ステロイド;禁煙剤;交感神経様作用薬;精神安定剤;血管拡張剤;ベータ作動薬;子宮収縮抑制剤、ならびにそれらの組み合わせからなる群より選択される、マトリクス。
- 請求項1に記載のマトリクスであって、前記治療薬、予防薬、または診断薬が、乱用される傾向のある薬剤である、マトリクス。
- 請求項1に記載のマトリクスであって、該マトリクスが、カプセル中に封入される、マトリクス。
- 請求項14に記載のマトリクスであって、前記カプセルが、軟ゼラチンカプセル、硬ゼラチンカプセル、および非ゼラチン軟カプセルからなる群より選択される、マトリクス。
- 請求項1に記載のマトリクスであって、前記薬学的に活性な物質の放出が、24時間まで調節される、マトリクス。
- 請求項1から請求項13、または請求項15または請求項16の任意の一つによって規定されるマトリクスを含む、カプセル。
- カプセル中に封入する二重制御放出マトリクスを製造する方法であって、ヒドロゲル形成ポリマー材料、および一つまたはそれより多い治療薬、予防薬、または診断薬を含む第2の速度調節バリアを、親水性ベヒクルを含む最初の速度調節バリア中に分散させて、請求項1から請求項16のいずれか1項によって規定されるマトリクスを形成する工程を包含する、方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US73040605P | 2005-10-26 | 2005-10-26 | |
US60/730,406 | 2005-10-26 | ||
PCT/US2006/042177 WO2007050975A2 (en) | 2005-10-26 | 2006-10-26 | Hydrophilic vehicle-based dual controlled release matrix system as capsule fill |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2013133677A Division JP2013216680A (ja) | 2005-10-26 | 2013-06-26 | 親水性ベヒクルに基づく二重制御された放出マトリクスシステム |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2009513669A JP2009513669A (ja) | 2009-04-02 |
JP2009513669A5 true JP2009513669A5 (ja) | 2009-12-17 |
JP5406530B2 JP5406530B2 (ja) | 2014-02-05 |
Family
ID=37801480
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008538048A Expired - Fee Related JP5406530B2 (ja) | 2005-10-26 | 2006-10-26 | 親水性ベヒクルに基づく二重制御された放出マトリクスシステム |
JP2013133677A Pending JP2013216680A (ja) | 2005-10-26 | 2013-06-26 | 親水性ベヒクルに基づく二重制御された放出マトリクスシステム |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2013133677A Pending JP2013216680A (ja) | 2005-10-26 | 2013-06-26 | 親水性ベヒクルに基づく二重制御された放出マトリクスシステム |
Country Status (6)
Country | Link |
---|---|
US (1) | US8333989B2 (ja) |
EP (1) | EP1959935A2 (ja) |
JP (2) | JP5406530B2 (ja) |
CN (1) | CN101360485B (ja) |
CA (1) | CA2627292C (ja) |
WO (1) | WO2007050975A2 (ja) |
Families Citing this family (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SI1553927T1 (sl) * | 2002-09-11 | 2010-12-31 | Elan Pharma Int Ltd | Z gelom stabilizirani nanodeläśni sestavki uäśinkovine |
US8852638B2 (en) | 2005-09-30 | 2014-10-07 | Durect Corporation | Sustained release small molecule drug formulation |
DK3095447T3 (da) | 2006-02-03 | 2022-01-31 | Opko Renal Llc | Behandling af vitamin d-insufficiens og -mangel med 25-hydroxyvitamin d2 og 25-hydroxyvitamin d3 |
HUE037309T2 (hu) | 2006-06-21 | 2018-08-28 | Opko Ireland Global Holdings Ltd | Terápia D-vitamin telítési szer alkalmazásával és D-vitamin hormon helyettesítõ szer |
KR20190028822A (ko) | 2007-04-25 | 2019-03-19 | 사이토크로마 인코포레이티드 | 비타민 d 화합물과 밀랍성 담체를 포함하는 경구 조절성 방출 조성물 |
CA2683514C (en) | 2007-04-25 | 2019-07-09 | Proventiv Therapeutics, Llc | Method of safely and effectively treating and preventing secondary hyperparathyroidism in chronic kidney disease |
CN104257667B (zh) | 2007-04-25 | 2019-06-04 | 欧普科Ip 控股Ii 有限公司 | 治疗维生素d不足和缺乏、继发性甲状旁腺功能亢进症和维生素d-响应疾病的方法和组合物 |
BRPI0811319A2 (pt) | 2007-05-25 | 2015-02-10 | Tolmar Therapeutics Inc | Composição fluida, método de formação de uma composição fluida, implante biodegrádavel formado in situ, método de formação de um implante biodegradável in situ, kit, implante e método de trataento |
EP2281058B1 (en) | 2008-04-02 | 2016-06-29 | Opko Ireland Global Holdings, Ltd. | Methods, compositions, uses, and kits useful for vitamin d deficiency and related disorders |
CN101491549B (zh) * | 2009-02-23 | 2011-08-03 | 四川珍珠制药有限公司 | 一种中药软胶囊及其制备方法 |
CN101485707B (zh) * | 2009-02-23 | 2011-05-18 | 四川珍珠制药有限公司 | 一种灵丹草软胶囊及其制备方法 |
WO2011123476A1 (en) | 2010-03-29 | 2011-10-06 | Cytochroma Inc. | Methods and compositions for reducing parathyroid levels |
US9272044B2 (en) | 2010-06-08 | 2016-03-01 | Indivior Uk Limited | Injectable flowable composition buprenorphine |
GB2481017B (en) | 2010-06-08 | 2015-01-07 | Rb Pharmaceuticals Ltd | Microparticle buprenorphine suspension |
US20150250750A1 (en) * | 2012-10-16 | 2015-09-10 | Wockhardt Limited | Pharmaceutical compostions of diclofenac or salts thereof |
US20150238451A1 (en) * | 2012-10-19 | 2015-08-27 | Wockhardt Limited | Pharmaceutical compositions of diclofenac or salts thereof |
KR101847947B1 (ko) | 2013-03-15 | 2018-05-28 | 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 | 안정화되고 변형된 비타민 d 방출 제형 |
US20140271837A1 (en) * | 2013-03-15 | 2014-09-18 | Warner Chilcott Company, Llc | Pharmaceutical soft gelatin capsule dosage form |
JP6335270B2 (ja) | 2013-03-15 | 2018-05-30 | ワーナー チルコット カンパニー, エルエルシーWarner Chilcott Company, Llc | 変性グアーガムを用いる医薬ソフトゼラチンカプセル剤形 |
US10420729B2 (en) | 2013-03-15 | 2019-09-24 | R.P. Scherer Technologies, Llc | Abuse resistant capsule |
JP6539274B2 (ja) | 2013-08-12 | 2019-07-03 | ファーマシューティカル マニュファクチュアリング リサーチ サービシズ,インコーポレーテッド | 押出成形された即放性乱用抑止性丸剤 |
WO2015095391A1 (en) | 2013-12-17 | 2015-06-25 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
US9492444B2 (en) | 2013-12-17 | 2016-11-15 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
US10098863B2 (en) | 2014-02-28 | 2018-10-16 | Banner Life Sciences Llc | Fumarate esters |
EP3501510B1 (en) | 2014-02-28 | 2020-07-01 | Banner Life Sciences LLC | Controlled release enteric soft capsules of fumarate esters |
US9326947B1 (en) | 2014-02-28 | 2016-05-03 | Banner Life Sciences Llc | Controlled release fumarate esters |
US9636318B2 (en) | 2015-08-31 | 2017-05-02 | Banner Life Sciences Llc | Fumarate ester dosage forms |
GB201404139D0 (en) | 2014-03-10 | 2014-04-23 | Rb Pharmaceuticals Ltd | Sustained release buprenorphine solution formulations |
US10772842B2 (en) | 2015-01-09 | 2020-09-15 | Patheon Softgels Inc. | Abuse-deterrent opioids |
US10182992B2 (en) | 2014-04-07 | 2019-01-22 | Patheon Softgels Inc. | Abuse-deterrent controlled release formulations |
JP6371463B2 (ja) | 2014-07-17 | 2018-08-08 | ファーマシューティカル マニュファクチュアリング リサーチ サービシズ,インコーポレーテッド | 即時放出性乱用抑止性液体充填剤形 |
EP3193925A2 (en) | 2014-08-07 | 2017-07-26 | OPKO Ireland Global Holdings, Ltd. | Adjunctive therapy with 25-hydroxyvitamin d |
US20160106737A1 (en) | 2014-10-20 | 2016-04-21 | Pharmaceutical Manufacturing Research Services, Inc. | Extended Release Abuse Deterrent Liquid Fill Dosage Form |
CA2978269A1 (en) * | 2015-03-02 | 2016-09-09 | Bionpharma Healthcare Llc | Immediate release soluble ibuprofen compositions |
KR20230054752A (ko) | 2016-03-28 | 2023-04-25 | 옵코 아일랜드 글로벌 홀딩스 리미티드 | 비타민 d 치료 방법 |
WO2018138607A1 (en) * | 2017-01-24 | 2018-08-02 | Nestec Sa | Compositions comprising anti-fel d1 antibodies and methods for reducing at least one symptom of human allergy to cats |
US11903918B2 (en) | 2020-01-10 | 2024-02-20 | Banner Life Sciences Llc | Fumarate ester dosage forms with enhanced gastrointestinal tolerability |
MX2023004441A (es) * | 2020-10-16 | 2023-05-08 | Scherer Technologies Llc R P | Composiciones de relleno de liberacion controlada y capsulas que las contienen. |
Family Cites Families (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3947600A (en) * | 1973-10-12 | 1976-03-30 | General Foods Corporation | Dipeptide sweetening of comestibles |
US4708834A (en) * | 1986-05-01 | 1987-11-24 | Pharmacaps, Inc. | Preparation of gelatin-encapsulated controlled release composition |
BE1003009A5 (fr) * | 1989-02-09 | 1991-10-22 | Sandoz Sa | Nouvelles compositions pharmaceutiques a base de cyclosporines. |
JPH0717498B2 (ja) * | 1989-05-31 | 1995-03-01 | 興和株式会社 | 鎮咳去痰ソフトカプセル剤 |
CA2017916C (en) * | 1989-06-07 | 1999-02-02 | Minoru Aoki | Etoposide preparations |
DE69226950T2 (de) * | 1991-04-08 | 1999-05-12 | Nippon Shinyaku Co Ltd | Kapsel mit Langzeitwirkung fuer die Adhäsion im Gastrointestinaltrakt |
US5505961A (en) * | 1993-08-05 | 1996-04-09 | R. P. Scherer Corporation | Gelatin capsules containing a highly concentrated acetaminophen solution |
GB9322314D0 (en) | 1993-10-29 | 1993-12-15 | Scherer Ltd R P | Foam generating capsules |
CA2181241C (en) * | 1994-01-24 | 2000-04-25 | Dadi Jamshed Dhabhar | Process for solubilizing difficultly soluble pharmaceutical actives |
US5447729A (en) * | 1994-04-07 | 1995-09-05 | Pharmavene, Inc. | Multilamellar drug delivery systems |
US5641512A (en) * | 1995-03-29 | 1997-06-24 | The Procter & Gamble Company | Soft gelatin capsule compositions |
FR2748209B1 (fr) | 1996-05-06 | 1998-06-05 | Adir | Composition pharmaceutique a base de matrices lipophiles stabilisees pour la liberation controlee de principes actifs |
US6027746A (en) * | 1997-04-23 | 2000-02-22 | Warner-Lambert Company | Chewable soft gelatin-encapsulated pharmaceutical adsorbates |
BE1011363A3 (fr) * | 1997-09-11 | 1999-08-03 | Smb Technology | Capsules semi-solides autoemulsionnables matricielles a action prolongee. |
GB2331458B (en) | 1997-11-21 | 2002-07-31 | Gursharan Singh Moonga | Solubilising systems for difficult pharmaceutical actives for preparing concentrated stable solutions for encapsulation into soft gelatine |
EP1049459B1 (en) * | 1998-01-20 | 2009-04-22 | Applied Analytical Industries, Inc. | Oral liquid compositions |
US6365180B1 (en) * | 1998-01-20 | 2002-04-02 | Glenn A. Meyer | Oral liquid compositions |
FR2782006B1 (fr) * | 1998-08-07 | 2002-04-19 | Gattefosse Ets Sa | Composition a liberation prolongee apte a former une micro-emulsion |
US6251426B1 (en) * | 1999-09-02 | 2001-06-26 | Banner Pharmacaps, Inc. | Ibuprofen-containing softgels |
MXPA02003190A (es) * | 1999-09-27 | 2002-09-30 | American Cyanamid Co | Formulacion para portadores farmaceuticos. |
DE60028754T2 (de) * | 1999-11-12 | 2007-05-31 | Abbott Laboratories, Abbott Park | Feste dispersion mit ritonavir, fenofibrat oder griseofulvin |
US6607736B2 (en) * | 1999-12-20 | 2003-08-19 | Shiseido Company, Ltd. | Skin preparations for external use |
US6491950B1 (en) | 2000-08-07 | 2002-12-10 | Kos Pharmaceuticals, Inc. | Controlled release pharmaceutical composition |
US6524615B2 (en) * | 2001-02-21 | 2003-02-25 | Kos Pharmaceuticals, Incorporated | Controlled release pharmaceutical composition |
US20030105141A1 (en) * | 2001-04-17 | 2003-06-05 | Ping Gao | Finely self-emulsifiable pharmaceutical composition |
JP2003055254A (ja) * | 2001-08-17 | 2003-02-26 | Toyo Capsule Kk | 経口投与用シクロスポリン製剤 |
US7029698B2 (en) * | 2001-11-21 | 2006-04-18 | R.P. Scherer Technologies, Inc. | Acetaminophen compositions |
WO2003061626A1 (en) * | 2002-01-18 | 2003-07-31 | Control Delivery Systems, Inc. | Polymeric gel system for the controlled delivery of codrugs |
IL164163A0 (en) * | 2002-04-09 | 2005-12-18 | Pharmacia Corp | Process for preparing a finely self-emulsifiable pharmaceutical composition |
FR2838349B1 (fr) * | 2002-04-15 | 2004-06-25 | Laurence Paris | Compositions liquides pour capsules molle a liberation prolongee et leur procede de fabrication |
US20040033257A1 (en) * | 2002-05-30 | 2004-02-19 | Strides Inc. | Pharmaceutical formulation in a drug delivery system and process for preparing the same |
WO2004004693A1 (en) * | 2002-07-05 | 2004-01-15 | Collgegium Pharmaceutical | Abuse-deterrent pharmaceutical compositions of opiods and other drugs |
PT2772250T (pt) | 2002-10-01 | 2017-01-02 | Banner Life Sciences Llc | Composição entérica para o fabrico de uma parede de cápsula mole |
ES2592504T3 (es) | 2003-07-17 | 2016-11-30 | Banner Life Sciences, LLC | Preparaciones de liberación controlada |
US20050096365A1 (en) | 2003-11-03 | 2005-05-05 | David Fikstad | Pharmaceutical compositions with synchronized solubilizer release |
WO2005070399A1 (en) * | 2004-01-09 | 2005-08-04 | Wyeth | Microemulsions for pharmaceutical compositions |
WO2006133048A2 (en) * | 2005-06-03 | 2006-12-14 | Duramed Pharmaceuticals, Inc. | Pharmaceutical compositions comprising prostanoid-receptor agonists and methods of making and using the same |
-
2006
- 2006-10-26 CA CA2627292A patent/CA2627292C/en not_active Expired - Fee Related
- 2006-10-26 EP EP06826983A patent/EP1959935A2/en not_active Withdrawn
- 2006-10-26 WO PCT/US2006/042177 patent/WO2007050975A2/en active Application Filing
- 2006-10-26 JP JP2008538048A patent/JP5406530B2/ja not_active Expired - Fee Related
- 2006-10-26 CN CN2006800457275A patent/CN101360485B/zh not_active Expired - Fee Related
- 2006-10-26 US US11/553,356 patent/US8333989B2/en not_active Expired - Fee Related
-
2013
- 2013-06-26 JP JP2013133677A patent/JP2013216680A/ja active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2009513669A5 (ja) | ||
JP2009513657A5 (ja) | ||
JP4526384B2 (ja) | カンナビス活性成分の投与のためのフィルム型粘着性投与形態 | |
RU2408368C2 (ru) | Препараты соли бупропиона с модифицированным высвобождением | |
KR101159828B1 (ko) | 활성제 구성요소 및 활성제 층의 원위부에 억제제 구성요소를 포함하는 내변조성 경피제형 | |
CA2627292C (en) | Hydrophilic vehicle-based dual controlled release matrix system | |
KR101234940B1 (ko) | 안정한 서방출형의 경구 투여용 조성물 | |
JP2002532392A5 (ja) | ||
KR100893158B1 (ko) | 경피성 그라니세트론 | |
JP2005515966A5 (ja) | ||
JP2013216681A (ja) | カプセル充墳物としての親油性ベヒクルに基づく二重制御された放出マトリクスシステム | |
JP2007522248A (ja) | てんかんおよび他のcns障害の処置のための、nmdaレセプターアンタゴニストと抗てんかん薬との組み合わせ | |
JP2006514058A (ja) | 薬物の経口投与用の急速溶解フィルム | |
JP2023052045A (ja) | 重水素化ドンペリドン組成物、方法、及び調製 | |
JP2006515299A5 (ja) | ||
JP2008532967A5 (ja) | ||
Gijare et al. | Orodispersible Films: A systematic patent review | |
Chwieduk et al. | Fentanyl sublingual: in breakthrough pain in opioid-tolerant adults with cancer | |
CN102821754B (zh) | 多层熔融挤出膜 | |
Datir | Recent advances in mucoadhesive buccal drug delivery system and its marketed scope and opportunities | |
WO2015157729A1 (en) | Pharmaceutical formulations an comprising analgesic agent, a nonsteroidal anti-inflammatory agent, a gastric acid production suppressant and an anti-nauseant | |
KR20140121394A (ko) | 아캄프로세이트 제제, 그것의 사용 방법, 및 그것을 포함하는 조합 | |
KR20050021003A (ko) | 대마 활성 성분의 투여용 필름 형상의 점막접착성 투여 제형 | |
US6174899B1 (en) | Orally administered analgesic composition comprising myfadol | |
CN117545478A (zh) | 用于治疗慢性疼痛的透皮药物制剂 |